Adverse events (pain) · adults requiring axillary artery catheterisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (pain) · adults requiring radial artery catheterisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (pain) · adults requiring radial artery catheterisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event nausea and vomiting (0 to 24 hours) · SSNS in children
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Adverse events: renal insufficiency · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in adverse events: renal insufficiency compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether IV changes adverse events: bacterial infection compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Adverse events ‐ Calcium > 11 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in adverse events: bacterial infections compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · preventing poliomyelitis
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Serious adverse events · people with cancer pain
1 finding from 1 review